The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Leukemia

• Publication date

  2009-01-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2008.375PMID 19151774
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias

  2008cited by this paper
• Mutated and non‐mutated TP53 as targets in the treatment of leukaemia

  2008cited by this paper
• Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia

  2008cited by this paper
• Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial

  2007cited by this paper
• PRIMA‐1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion

  2006cited by this paper
• MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia

  2005cited by this paper
• Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

  2005cited by this paper
• A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.

  2004cited by this paper
• Coexpression of p53 protein and MDR functional phenotype in leukemias: The predominant association in chronic myeloid leukemia

  2004cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Mutations in the p53 Gene in Acute Myeloid Leukemia Patients Correlate with Poor Prognosis

  2002cited by this paper
• Live or let die: the cell's response to p53

  2002cited by this paper
• Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24‐color FISH

  2002cited by this paper
• Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

  2002cited by this paper
• The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

  2001cited by this paper
• Mutations in ras proto‐oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia

  2001cited by this paper
• Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.

  2001cited by this paper
• Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

  2000cited by this paper
• Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms.

  2000cited by this paper
• Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia

  2000cited by this paper
• Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.

  2000cited by this paper
• Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

  2000cited by this paper
• Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations.

  1999cited by this paper
• Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype

  1999cited by this paper
• Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation

  1998cited by this paper
• Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality

  1998cited by this paper
• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ.

  1998cited by this paper
• Analysis of the p53 gene mutations in acute myelogenous leukemia: The p53 gene mutations associated with a deletion of chromosome 17

  1995cited by this paper
• Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.

  1995cited by this paper
• p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

  1995cited by this paper
• Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia

  1994cited by this paper
• The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin.

  1994cited by this paper
• p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

  1994cited by this paper
• p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies

  1994cited by this paper
• p53 mutation is associated with progression in follicular lymphomas.

  1993cited by this paper
• Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis.

  1992cited by this paper
• P53 gene mutations in acute myeloid leukemia with 17p monosomy.

  1991cited by this paper
• Levels of p53 protein increase with maturation in human hematopoietic cells.

  1991cited by this paper
• Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases

  1989cited by this paper
• Kinetics of appearance of differentiation-associated characteristics in ML-1, a line of human myeloblastic leukemia cells, after treatment with 12-O-tetradecanoylphorbol-13-acetate, dimethyl sulfoxide or 1-beta-D-arabinofuranosylcytosine.

  1982cited by this paper
• An international system for human cytogenetic nomenclature

  1978cited by this paper

• TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approaches

  2026cites this paper
• Management of Acute Myeloid Leukemia: A Review.

  2026cites this paper
• TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

  2025cites this paper
• Biologic and Clinical Characteristics of Isochromosome der(17)(q10)t(15;17) in Acute Promyelocytic Leukemia

  2024cites this paper
• From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

  2024cites this paper
• Evaluating targeted therapies in older patients with TP53-mutated AML

  2024cites this paper
• Detection of novel PPP1R1B::STARD3 fusion transcript in acute myeloid leukemia: a case report

  2024cites this paper
• Therapy-related myeloid neoplasms with single-hit TP53 mutations share the clinical, molecular, and survival characteristics of their multi-hit counterparts

  2024cites this paper
• Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

  2023cites this paper
• How I treat AML incorporating the updated classifications and guidelines

  2023cites this paper
• Role of Cytogenetics and Fluorescence In Situ Hybridization in the Laboratory Workup of Acute Myeloid Leukemias

  2023cites this paper
• TP53 in AML and MDS: The new (old) kid on the block.

  2023cites this paper
• Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma

  2023cites this paper
• TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches

  2023cites this paper
• The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma

  2023cites this paper
• Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

  2023cites this paper
• Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome

  2023cites this paper
• Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma

  2023cites this paper
• Escape from T-cell–targeting immunotherapies in acute myeloid leukemia

  2023cites this paper
• The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.

  2023cites this paper
• Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.

  2023cites this paper
• Checkpoint Inhibitors in Acute Myeloid Leukemia

  2023cites this paper
• Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion

  2023cites this paper
• TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia

  2023cites this paper
• TP53 Mutant Acute Myeloid Leukemia: The Immune and Metabolic Perspective

  2022cites this paper
• Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors

  2022cites this paper
• The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions

  2022cites this paper
• Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype

  2022cites this paper
• Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?

  2022cites this paper
• Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome

  2022cites this paper
• Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia

  2022cites this paper
• Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model

  2022cites this paper
• Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives

  2022cites this paper
• Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

  2022cites this paper
• Copy Number Analysis in Cancer Diagnostic Testing.

  2022cites this paper
• Molecular and Cytogenetic Study of Acute Myelocytic Leukemia Patients in Kurdistan Region

  2022cites this paper
• Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach

  2021cites this paper
• Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

  2021cites this paper
• The potential role of nucleophosmin (NPM1) in the development of cancer

  2021cites this paper
• Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades.

  2021cites this paper
• Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy

  2021influential citation
• Prognostic Factors in AML

  2021cites this paper
• Development of TP53 mutations over the course of therapy for acute myeloid leukemia

  2021cites this paper
• Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?

  2021cites this paper
• Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia

  2021cites this paper
• Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia.

  2021cites this paper
• A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation

  2021cites this paper
• TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

  2021cites this paper
• TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

  2021cites this paper
• Acute myeloid leukemia: current progress and future directions

  2021cites this paper
• Case Report 1

  2020cites this paper
• Prognostic impact of cytogenetic evolution on the outcome of allogeneic stem cell transplantation in patients with acute myeloid leukemia in non-remission: A single institute analysis of 212 recipients.

  2020cites this paper
• Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.

  2020cites this paper
• Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia

  2020cites this paper
• Therapeutic Vulnerabilities of Transcription Factors in AML

  2020cites this paper
• TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

  2020cites this paper
• Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice

  2020cites this paper
• An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism

  2020cites this paper
• How we treat older patients with acute myeloid leukaemia

  2020cites this paper
• TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

  2020cites this paper
• Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia

  2020cites this paper
• Identification of relapse‐associated gene mutations by next‐generation sequencing in low‐risk acute myeloid leukaemia patients

  2020cites this paper
• Association Between TP53 Mutation and Prognosis in Wilms Tumor: A Meta-Analysis

  2020cites this paper
• A Novel Variant Rearrangement of the Rare Aberration dic(17;20)(p11.2;q11.2) Characterized by Array-CGH as an Insertion in a Patient with Myelodysplastic Syndrome of Multilineage Dysplasia (MDS-MLD)

  2020influential citation
• Current status and new treatment approaches in TP53 mutated AML.

  2019cites this paper
• Establishment and characterization of a novel childhood acute lymphoblastic leukemia cell line, HXEX-ALL1, with chromosome 9p and 17p deletions

  2019cites this paper
• Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia

  2019cites this paper
• TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia

  2019cites this paper
• Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer

  2019cites this paper
• The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy

  2019cites this paper
• The role of TP53 in acute myeloid leukemia: Challenges and opportunities

  2019cites this paper
• Clinical implications of TP53 mutations in a southeast asian cohort of acute myeloid leukaemia patients

  2018cites this paper
• Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why

  2018cites this paper
• P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse‐free survival

  2018cites this paper
• Significance of Cytogenetics in Leukemia Diagnostics

  2018cites this paper
• Next generation sequencing to identify multiple clinically relevant genetic lesions for the diagnosis of acute myeloid leukaemia

  2018cites this paper
• Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.

  2018cites this paper
• p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status

  2017cites this paper
• Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports

  2017cites this paper
• p53 pathway dysfunction in AML: beyond TP53 mutations

  2017cites this paper
• Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.

  2017cites this paper
• Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B‐Cell Acute Lymphoblastic Leukemia

  2017cites this paper
• Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia

  2017cites this paper
• Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology.

  2017cites this paper
• Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor

  2017cites this paper
• Identification of key pathways and genes in TP53 mutation acute myeloid leukemia: evidence from bioinformatics analysis

  2017cites this paper
• Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

  2017cites this paper
• Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.

  2017cites this paper
• Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition

  2017cites this paper
• Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera

  2017cites this paper
• A fluorescence in situ hybridization‐based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia

  2017cites this paper
• Identification of key pathways and genes in TP53 mutation acute myeloid leukemia: evidence from bioinformatics analysis

  2017cites this paper
• Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17.

  2017cites this paper
• Isochromosome 17q; A Novel Finding in Myeloid Sarcoma.

  2016cites this paper
• Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia

  2016cites this paper
• Clinicopathologic features and prognostic impact of isochromosome 17q in chronic myeloid leukemia patients

  2016cites this paper
• Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

  2016cites this paper
• TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

  2016cites this paper
• ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

  2016cites this paper
• Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

  2016cites this paper